RON SAYCO, CFA/CPA

CHIEF EXECUTIVE OFFICER

Ron Sayco is Chief Executive Officer at S1P Therapeutics. He received a BS degree from McIntire School of Commerce at the University of Virginia and an MBA from Stanford Graduate School of Business. Ron is a CFA Charterholder and CPA. He has worked in executive management, strategy, and finance roles for high growth businesses from startups to billion-dollar global enterprises. He has participated in over $3B in equity and debt financings and executed over $5B in M&A transactions. He is a Board Member of Checkup & Choices, a digital health platform focused on substance abuse and was formerly CFO of Merlin Cyber, a provider of cybersecurity solutions to the government. Prior to Merlin, Ron was CFO of OverHorizon, a satellite services company and a Board Member of 901D, a portfolio company of Graycliff Partners. Before Merlin, Ron held senior Strategy & Corporate Development roles for France-based Thales Group and UK-based BAE Systems.


KEVIN R. LYNCH, PHD

CHIEF SCIENTIFIC OFFICER

Kevin Lynch is Chief Scientific Officer at S1P Therapeutics. He received a BS degree from Penn State, earned his PhD from the University of Rhode Island and did a postdoc at Columbia University as a Ruth Kirschtein NIH trainee. He is currently Professor and Vice Chair of Pharmacology at the University of Virginia School of Medicine. Prof. Lynch has published more than 170 papers, is an inventor of over 30 issued and pending patents, and has been a co-founder of three biotech startup companies. He was named Inventor of the Year (2010) by UVA’s Patent Foundation, has consulted for several pharmaceutical industry firms, advises law firms engaged in patent litigation and has served on numerous NIH grant review panels. Prof. Lynch is an expert pharmacologist who has extensive experience in developing new drugs targeting proteins in the sphingosine 1-phosphate pathway.


WEBSTER SANTOS, PHD

VICE PRESIDENT AND HEAD OF MEDICINAL CHEMISTRY

Webster Santos is Vice President and Head of Medicinal Chemistry at S1P Therapeutics. He received his BS and PhD from the University of Virginia and trained at Harvard University as a Ruth Kirschtein NIH fellow. He is currently a Professor of Chemistry and Director of the Virginia Tech Center for Drug discovery. He has published over 120 papers, an inventor of over 20 issued and pending patents, and a co-founder of three biotech startup companies. He serves as a standing member of SBCB/CBP NIH study section and on the editorial board of Medicinal Research Reviews, Current Topics in Medicinal Chemistry and Molecules. He is a fellow of the Royal Society of Chemistry, received the Fralin-ICTAS Innovators award, American Chemical Society Young Investigator Award, Chemical Communications and Molecular Biosystems Emerging Investigator, and named as the Blackwood Junior Faculty Fellow of Life Sciences and A.C. Lilly Faculty Fellow of Drug Discovery at Virginia Tech. Dr. Santos is an expert medicinal chemist who has extensive experience in developing novel drugs targeting proteins in the sphingosine-1-phosphate pathway.